Table 2.
Comparison of clinical and laboratory data between survivors and nonsurvivors during index hospitalization.
| Survivor group | Nonsurvivor group | P | |
|---|---|---|---|
|
| |||
| N | 25 | 6 | NS |
| Age (yrs) | 67.25 (12.63) | 72.84 (15.23) | .45 |
| Gender (male/female) | 19/6 | 5/1 | .69 |
| BMI (kg/m2) | 21.05 (7.66) | 18.37 (5.79) | .87 |
| GOLD stage (I + II) | 18 | 1 | .012 |
| GOLD stage (III + IV) | 7 | 5 | .012 |
| Ischemic heart disease (n) | 8 | 3 | .41 |
| Diabetes (n) | 9 | 4 | .17 |
| Osteoporosis (n) | 6 | 3 | .21 |
| Length of hospitalization (median, days) | 9.68 (3.59) | 19.72 (6.58) | <.001 |
| Antibiotic treatment(n) | 21 | 6 | .29 |
| White blood cell count (109/L) | 8.83 (3.25) | 11.33 (5.57) | .15 |
| pH | 7.35 (0.07) | 7.30 (0.16) | .25 |
| PaCO2 (mmHg) | 50.96 (18.08) | 65.17 (25.11) | .14 |
| PaO2 (mmHg) | 71.48 (9.85) | 64.34 (11.85) | .11 |
| hs CRP (mg/L) | 7.48 (2.93) | 9.97 (3.05) | .091 |
| PCT (μg/L) | 0.46 (0.18) | 0.62 (0.34) | .15 |
| nCD64 (%) | 2.59 (0.85) | 3.87 (0.65) | .002 |
Values are mean (standard deviation). Statistically significant values are bolded.